Cellect fbs gold

Vero E6 and HEK 293T cells expressing human ACE2 cells (NR-52511, BEI Resources, NIAID, NIH, RRID: CVCL_A7UK) were cultured in complete media containing Dulbecco’s modified Eagle medium (#CC3004, Cell Clone, Genetix, New Delhi, India) with 10% CELLECT FBS GOLD (#2916754, MP Biomedicals, Santa Ana, CA, USA), 100 IU/mL Penicillin, 100 μg/mL Streptomycin, and 0.25 μg/mL Amphotericin-B (Antibiotic-Antimycotic Solution, #A5955, Sigma-Aldrich, St. Louis, MO, USA).
SARS-CoV-2 isolates (Hong Kong/VM20001061/2020, NR-52282; hCoV-19/USA/MD-HP05285/2021, NR-55671 (Delta Variant)) were obtained from BEI Resources, the NIAID, and the NIH and were propagated and tittered by using standard plaque assay in Vero E6 cells. The Omicron variant was isolated from the patient sample from the South Karnataka region, India, and was confirmed using S gene target failure PCR. All the experiments pertaining to live SARS-CoV-2 were performed in a viral biosafety level 3 laboratory at CIDR, IISc, Bangalore.

HEK293T cells expressing human ACE2 (HEK-ACE2, BEI Resources, Cat no. NR-52511) were cultured in complete media containing Dulbecco’s modified Eagle medium (Cell Clone, Cat no. CC3004) with 10% CELLect FBS Gold (MP Biomedicals, Cat no. 2916754), 100 IU/mL penicillin, 100 μg/mL streptomycin and 0.25 μg/mL amphotericin-B (Sigma, Cat no. A5955). SARS-CoV-2 isolates (Cat no. NR-52282, Hong Kong/VM20001061/2020, WT; Cat no. NR-55671, hCoV-19/USA/MD-HP05285/2021, Delta variant), were obtained from BEI Resources and propagated and titrated using the standard plaque assay in Vero E6 cells. All experiments on live SARS-CoV-2 virus were performed at Biosafety Level 3.